Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
about
Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphomaEnhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasNitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeuticsNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewStructural basis for recognition of CD20 by therapeutic antibody RituximabTargeting NF-kappaB in Waldenstrom macroglobulinemiaA hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibodyGrowth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6.Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcomeFCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cellsF-box protein 10, an NF-κB-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathwayLenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximabHow does B cell depletion therapy work, and how can it be improved?Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamicsAnti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells.Investigating endogenous peptides and peptidases using peptidomicsEight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.The NF-kappaB signalling pathway: a therapeutic target in lymphoid malignancies?In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRSEpigenetic changes and nuclear factor-κB activation, but not microRNA-224, downregulate Raf-1 kinase inhibitor protein in triple-negative breast cancer SUM 159 cells.Pathogenesis and therapy of cutaneous lymphomas--progress or impasse?Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.Rituximab in refractory autoimmune bullous diseases.Bcl-2 expression in rituximab refractory cutaneous B-cell lymphomaImmunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphomaThe impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patientsRituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B-cell lymphoma cells and their association with clinical featuresCell death in health and diseaseR-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas.Rituximab and chemotherapy in diffuse large B-cell lymphoma.Anti-CD20 monoclonal antibodies: historical and future perspectives.
P2860
Q24243100-CB7A43F7-3A32-4783-92B6-B20736A9D9ABQ24813078-51FA732D-AA0E-4159-BC85-5AD08704724AQ26749139-27733D10-F8A8-4A75-8F51-059976419C42Q26782525-A2E12048-2B42-4138-89D2-3A6926ECCEFCQ27304386-6DBE8284-E965-43B5-A469-2B697A7AB92EQ27644280-B0416295-E10C-4CC9-B584-F230BA4434EAQ28272373-2CDD87B0-BD86-4FED-B81F-7F0A0C9390F1Q30420026-138EB2C2-AA59-44A3-BD79-98A763C634E6Q33275612-F9626675-0E22-4330-824B-1F3C9C86CEF4Q33392868-67611175-FF16-4584-8568-DE555E39FFABQ33903709-F0AB0966-0F8F-44A8-9BB0-8A5901742D31Q34088194-678033EB-0637-43D7-8C31-C3365E5FC08FQ34139663-595B1FBE-8D09-4AF4-984D-0692FB914983Q34160097-842261CE-CCA2-49AC-AA27-91500050F186Q34278096-D620F1C0-18E6-4CF0-B2FE-B68F19161D12Q34700655-00E988C2-1A5B-4050-8F9B-380A4C1B24A0Q35525404-E8680482-DB2A-4C03-A298-B89757F9ED5DQ35579475-8972DD3F-0CF4-4B4D-9992-3B86A1BF5AEFQ35919697-C56F0333-417A-48CB-A863-34D0FA75C67CQ36060249-162DA776-5726-4C0C-AF93-2EC9B2F3D55EQ36163374-7373B6BC-6B51-40C6-A34D-F738E5C298B7Q36219690-219199B5-E586-486C-80B2-B7DA785BE753Q36268334-4602EEC2-0B03-4762-BED7-663DB6018660Q36289235-4115EFCB-D958-4DA8-B469-369F3394C908Q36334655-2B02A2F5-D643-4B72-B7A5-AB8A9205D16AQ36455996-2DCFCBD1-F3EA-40A0-8CC8-B27365C3A8E4Q36460314-A6973BEE-7105-4AC0-956C-84B4117FBD1DQ36484979-227510F3-C2A4-495F-AEE7-A2339416729DQ36609581-6DBCD051-D612-4FD3-861C-93BF9AECED99Q36797398-8E1A3C7F-927D-47EB-B428-84DC39E38742Q36807184-DCAFAC82-2B9C-4DE8-9926-401FB029E1B8Q36822155-5E9F2A7A-10D4-42C9-82B8-0F00E7E16FADQ36826060-5462F85B-6414-4296-99EB-0184C82E091AQ36832106-F027EBCC-621F-4A31-8C8F-B1DD0BEB004DQ36918646-22F92397-C084-44F7-952C-81C31577AB1DQ37010413-4E838D07-C55A-4FCD-A58A-B5EE1AFBFA3CQ37183688-5AE03793-6015-4B21-B9E4-65FDE8E452B2Q37271831-4781B43C-0A20-43E9-87B0-905DF12C5A64Q37508007-904C0213-2F73-434E-A186-160A32C3165DQ37601775-6EEDFC80-6498-4819-A99A-DF60EEBC918D
P2860
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Cellular and molecular signal ...... and therapeutic intervention.
@ast
Cellular and molecular signal ...... and therapeutic intervention.
@en
type
label
Cellular and molecular signal ...... and therapeutic intervention.
@ast
Cellular and molecular signal ...... and therapeutic intervention.
@en
prefLabel
Cellular and molecular signal ...... and therapeutic intervention.
@ast
Cellular and molecular signal ...... and therapeutic intervention.
@en
P2860
P356
P1433
P1476
Cellular and molecular signal ...... and therapeutic intervention.
@en
P2093
Ali R Jazirehi
Benjamin Bonavida
P2860
P2888
P304
P356
10.1038/SJ.ONC.1208349
P407
P577
2005-03-01T00:00:00Z